With the acquisition, BioNTech will obtain full global rights to the late-stage clinical asset BNT327/PM8002, an investigational bispecific antibody targeting PD-L1 and VEGF-A. The transaction is part ...
CTC PD-L1 assay enables longitudinal monitoring of PD-L1 status in lung cancer patients and may help to advance personalised treatment GUILDFORD, UNITED KINGDOM / ACCESSWIRE / November 15, 2024 / ...
RAHWAY, NJ, USA I 14, 2024 I Merck (NYSE: MRK), known as MSD outside of the United States and Canada, and LaNova Medicines Ltd. (LaNova), a privately ...
Checkpoint Therapeutics' cosibelimab shows strong efficacy in treating cSCC. Learn why CKPT stock could see significant gains ...
As Merck prepares for its blockbuster immunotherapy Keytruda to face generic competition, it’s investing in a new cancer drug from LaNova.
Researchers from Auburn University, partnering with the University of Basel in Switzerland, have discovered a new way to make ...
During a Case-Based Roundtable® event, Matthew Campbell, MD, MS, moderated a discussion on treatment for a 61-year-old ...
Key data: These results compare favourably to the 22.0-month median OS, 9.0-month median PFS, and 24-month OS rate of 45.5% from a registrational trial of anti-PD-1 and doublet chemotherapy in ...
Zacks.com on MSN17h
BNTX to Boost Oncology Pipeline With Biotheus Acquisition, Stock UpBioNTech SE BNTX announced that it has entered into a definitive agreement to acquire China-based biotech, Biotheus, to ...
Immutep's INSIGHT-003 Phase 1 trial reports promising survival data for 1L NSCLC treatment using eftilagimod alpha, Keytruda, ...
19h
Media ReleaseMature data in patients with a minimum follow-up of 22 months (N=21) shows excellent results, well above historical controls and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback